ConductScience.org, home

Paper8324745

Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics.

Hinman LM and 5 others. Cancer Res, 1993. Cited by 187 papers, by iCite.

Cite this record

ConductScience Library. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Papers, record 8324745. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8324745

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics.
PubMed
Journal
Cancer Res
PubMed
Year
1993
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
187
iCite
Relative citation ratio, by iCite
4.63
iCite
Revised in PubMed
2022-02-24
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Hinman LML M
2Hamann PRP R
3Wallace RR
4Menendez ATA T
5Durr FEF E
6Upeslacis JJ

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-Bacterial AgentsMajor topic
Antibiotics, AntineoplasticMajor topic
Aminoglycosides
Animals
Antibodies, Monoclonal
Breast Neoplasms
Drug Screening Assays, Antitumor
Feasibility Studies
Female
Humans
Leukemia P388
Mice
Mice, Nude
Molecular Structure
Structure-Activity Relationship
Tumor Cells, Cultured

Source PubMed

Download CSV of topics

Cited by56

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 187 citations.

PMIDTitleJournalYearIn PapersSource
42747695Outcomes by Body Mass Index in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Treated with Inotuzumab Ozogamicin.Target Oncol2026https://conductscience.org/library/papers/42747695PubMed
41184856Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions.Mol Cancer2025https://conductscience.org/library/papers/41184856PubMed
39568595Technical, preclinical, and clinical developments of Fc-glycan-specific antibody-drug conjugates.RSC Med Chem2025https://conductscience.org/library/papers/39568595PubMed
39201338Antibody Drug Conjugates for Cancer Therapy: From Metallodrugs to Nature-Inspired Payloads.Int J Mol Sci2024https://conductscience.org/library/papers/39201338PubMed
38665947Antibody-drug conjugates in urothelial carcinoma: scientometric analysis and clinical trials analysis.Front Oncol2024https://conductscience.org/library/papers/38665947PubMed
37336296Modulating antibody effector functions by Fc glycoengineering.Biotechnol Adv2023https://conductscience.org/library/papers/37336296PubMed
35646299Relapsed acute lymphoblastic leukaemia after allogeneic stem cell transplantation: a therapeutic dilemma challenging the armamentarium of immunotherapies currently available (case reports).Ther Adv Hematol2022https://conductscience.org/library/papers/35646299PubMed
35318309Antibody drug conjugate: the "biological missile" for targeted cancer therapy.Signal Transduct Target Ther2022https://conductscience.org/library/papers/35318309PubMed
34944865Immunotherapy as a Turning Point in the Treatment of Acute Myeloid Leukemia.Cancers (Basel)2021https://conductscience.org/library/papers/34944865PubMed
34641391An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy.Molecules2021https://conductscience.org/library/papers/34641391PubMed
34155147Uncialamycin-based antibody-drug conjugates: Unique enediyne ADCs exhibiting bystander killing effect.Proc Natl Acad Sci U S A2021https://conductscience.org/library/papers/34155147PubMed
32319494Perspectives from nearly five decades of total synthesis of natural products and their analogues for biology and medicine.Nat Prod Rep2020https://conductscience.org/library/papers/32319494PubMed
31816964Antibody Structure and Function: The Basis for Engineering Therapeutics.Antibodies (Basel)2019https://conductscience.org/library/papers/31816964PubMed
31643051Click Chemistry Conjugations.Methods Mol Biol2020https://conductscience.org/library/papers/31643051PubMed
31360093Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia.Blood Lymphat Cancer2018https://conductscience.org/library/papers/31360093PubMed
31104399MALDI-MS: a Rapid and Reliable Method for Drug-to-Antibody Ratio Determination of Antibody-Drug ConjugatesIran Biomed J2019https://conductscience.org/library/papers/31104399PubMed
30898889The EMA Review of Mylotarg (Gemtuzumab Ozogamicin) for the Treatment of Acute Myeloid Leukemia.Oncologist2019https://conductscience.org/library/papers/30898889PubMed
30093401Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group.Haematologica2019https://conductscience.org/library/papers/30093401PubMed
30087554Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia.Drug Des Devel Ther2018https://conductscience.org/library/papers/30087554PubMed
29296758Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study.Blood Adv2017https://conductscience.org/library/papers/29296758PubMed

See all 56 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/8324745

GET https://conductscience.org/api/papers/v1/8324745/cited_by?page=2